Kenneth J. McGrath net worth and biography

Kenneth McGrath Biography and Net Worth

Kenneth J. McGrath was named Chief Financial Officer in August 2022. In this role, he is responsible for overseeing finance, accounting, tax, and information technology, including cybersecurity. Prior to joining OraSure, Mr. McGrath spent eight years at Quest Diagnostics, most recently serving as Vice President in Finance, where he led an organization responsible for more than $7 billion in revenue. He helped build Quest’s Advanced Diagnostics business accelerating growth, while improving profitability with expanded capabilities and innovation. His expertise also includes value creation via partnerships and successfully assessing and integrating multiple acquisitions. Mr. McGrath’s finance operating responsibility also spans information technology, R&D and medical functions, as well as commercial regions. Prior to his time at Quest, Mr. McGrath held various leadership positions in finance operating roles at Johnson & Johnson, Inc. He began his career at Ford Motor Company. He received an M.B.A from the University of Michigan and a B.S. from the University of Notre Dame. He is a CFA Charterholder.

What is Kenneth J. McGrath's net worth?: The estimated net worth of Kenneth J. McGrath is at least $1.72 million as of March 20th, 2026. Mr. McGrath owns 589,562 shares of OraSure Technologies stock worth more than $1,721,521 as of March 31st. This net worth evaluation does not reflect any other investments that Mr. McGrath may own. Learn More about Kenneth J. McGrath's net worth.
How do I contact Kenneth J. McGrath?: The corporate mailing address for Mr. McGrath and other OraSure Technologies executives is 220 EAST FIRST STREET, BETHLEHEM PA, 18015. OraSure Technologies can also be reached via phone at (610) 882-1820 and via email at [email protected]. Learn More on Kenneth J. McGrath's contact information.
Has Kenneth J. McGrath been buying or selling shares of OraSure Technologies?: Over the course of the past ninety days, Kenneth J. McGrath has bought $160,702.00 of OraSure Technologies stock. Most recently, on Friday, March 20th, Kenneth J. Mcgrath bought 32,300 shares of OraSure Technologies stock. The stock was acquired at an average cost of $2.93 per share, with a total value of $94,639.00. Following the completion of the transaction, the chief financial officer now directly owns 589,562 shares of the company's stock, valued at $1,727,416.66. Learn More on Kenneth J. McGrath's trading history.
Who are OraSure Technologies' active insiders?: OraSure Technologies' insider roster includes Carrie Eglinton Manner (President and Chief Executive Officer), Kenneth McGrath (CFO), and Kathleen Weber (Chief Product Officer). Learn More on OraSure Technologies' active insiders.
Are insiders buying or selling shares of OraSure Technologies?: During the last year, OraSure Technologies insiders bought shares 4 times. They purchased a total of 108,643 shares worth more than $321,407.00. The most recent insider tranaction occured on March, 20th when CFO Kenneth J Mcgrath bought 32,300 shares worth more than $94,639.00. Insiders at OraSure Technologies own 3.9% of the company. Learn More about insider trades at OraSure Technologies.
Information on this page was last updated on 3/20/2026.

Kenneth J. McGrath Insider Trading History at OraSure Technologies

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/20/2026	Buy	32,300	$2.93	$94,639.00	589,562
3/13/2026	Buy	22,021	$3.00	$66,063.00	557,262
2/27/2025	Buy	64,000	$3.15	$201,600.00	371,013

Kenneth J. McGrath Buying and Selling Activity at OraSure Technologies

OraSure Technologies Company Overview

OraSure Technologies, Inc., together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of void urine samples; and microbiome laboratory testing and analytical services. In addition, the company provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Additionally, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, nutrition, companion animal, and environmental markets. OraSure Technologies, Inc. was incorporated in 2000 and is based in Bethlehem, Pennsylvania.

Today's Range

Now: $2.98

$2.92

$3.01

50 Day Range

MA: $2.90

$2.59

$3.20

2 Week Range

Now: $2.98

$2.08

$3.82

Volume

92,128 shs

Average Volume

535,161 shs

Market Capitalization

$205.66 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.88